Literature DB >> 11507231

Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63.

T K Kenyon1, J Lynch, J Hay, W Ruyechan, C Grose.   

Abstract

Varicella-zoster virus (VZV) codes for a protein serine kinase called ORF47; the herpes simplex virus (HSV) homolog is UL13. No recombinant alphaherpesvirus serine kinase has been biologically active in vitro. We discovered that preservation of the intrinsic kinase activity of recombinant VZV ORF47 required unusually stringent in vitro conditions, including physiological concentrations of polyamines. In this assay, ORF47 phosphorylated two VZV regulatory proteins: the ORF62 protein (homolog of HSV ICP4) and the ORF63 protein (homolog of HSV ICP22). Of interest, ORF47 kinase also coprecipitated ORF63 protein from the kinase assay supernatant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507231      PMCID: PMC115131          DOI: 10.1128/jvi.75.18.8854-8858.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Varicella-zoster virus gene expression in latently infected and explanted human ganglia.

Authors:  P G Kennedy; E Grinfeld; J E Bell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus.

Authors:  R F Smith; T F Smith
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

4.  Infection of human T lymphocytes with varicella-zoster virus: an analysis with viral mutants and clinical isolates.

Authors:  W Soong; J C Schultz; A C Patera; M H Sommer; J I Cohen
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Physical interaction between two varicella zoster virus gene regulatory proteins, IE4 and IE62.

Authors:  M L Spengler; W T Ruyechan; J Hay
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

6.  Interaction of polyamines and magnesium with casein kinase II.

Authors:  G M Hathaway; J A Traugh
Journal:  Arch Biochem Biophys       Date:  1984-08-15       Impact factor: 4.013

7.  Effects of polyamines, polyamine synthesis inhibitors, and polyamine analogs on casein kinase II using Myc oncoprotein as substrate.

Authors:  N Gündoguş-Ozcanli; C Sayilir; W E Criss
Journal:  Biochem Pharmacol       Date:  1999-07-15       Impact factor: 5.858

8.  Functional interaction between c-Abl and the p21-activated protein kinase gamma-PAK.

Authors:  J Roig; P T Tuazon; P A Zipfel; A M Pendergast; J A Traugh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

9.  Varicella-zoster virus (VZV) ORF65 virion protein is dispensable for replication in cell culture and is phosphorylated by casein kinase II, but not by the VZV protein kinases.

Authors:  J I Cohen; H Sato; S Srinivas; K Lekstrom
Journal:  Virology       Date:  2001-02-01       Impact factor: 3.616

10.  Stimulation of enzymatic activity in filament preparations of casein kinase II by polylysine, melittin, and spermine.

Authors:  M D Mamrack
Journal:  Mol Cell Biochem       Date:  1989-02-21       Impact factor: 3.396

View more
  38 in total

1.  The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase.

Authors:  Paula M Krosky; Moon-Chang Baek; Wan Jin Jahng; Imma Barrera; Robert J Harvey; Karen K Biron; Donald M Coen; Phiroze B Sethna
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 2.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

3.  ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo.

Authors:  Anne Schaap-Nutt; Marvin Sommer; Xibing Che; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 4.  Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model.

Authors:  Chia-Chi Ku; Jaya Besser; Allison Abendroth; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Varicella-zoster virus ORF47 protein kinase, which is required for replication in human T cells, and ORF66 protein kinase, which is expressed during latency, are dispensable for establishment of latency.

Authors:  Hitoshi Sato; Lesley Pesnicak; Jeffrey I Cohen
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  The varicella-zoster virus (VZV) ORF9 protein interacts with the IE62 major VZV transactivator.

Authors:  Cristian Cilloniz; Wallen Jackson; Charles Grose; Donna Czechowski; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Nuclear import of the varicella-zoster virus latency-associated protein ORF63 in primary neurons requires expression of the lytic protein ORF61 and occurs in a proteasome-dependent manner.

Authors:  Matthew S Walters; Christos A Kyratsous; Shilin Wan; Saul Silverstein
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Identification of phosphorylated residues on varicella-zoster virus immediate-early protein ORF63.

Authors:  Niklaus H Mueller; Matthew S Walters; Roland A Marcus; Laurie L Graf; Jessica Prenni; Don Gilden; Saul J Silverstein; Randall J Cohrs
Journal:  J Gen Virol       Date:  2010-01-20       Impact factor: 3.891

Review 9.  Polyamines and Their Role in Virus Infection.

Authors:  Bryan C Mounce; Michelle E Olsen; Marco Vignuzzi; John H Connor
Journal:  Microbiol Mol Biol Rev       Date:  2017-09-13       Impact factor: 11.056

10.  Substrate specificity of the herpes simplex virus type 2 UL13 protein kinase.

Authors:  Gina L Cano-Monreal; John E Tavis; Lynda A Morrison
Journal:  Virology       Date:  2008-01-22       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.